Effective Combination Therapy of Deferiprone and deferoxamine for the Rapid Clearance of Excess Cardiac IRON and the Prevention of Heart Disease in Thalassemia. The Protocol of the International Committee on Oral Chelators

Abstract

The International Committee on Oral Chelators (ICOC) combination therapy protocol involving the administration of deferiprone (L1) during the day (80–110 mg/kg/day) and deferoxamine (DFO) (40–60 mg/kg at least 3 days/week) during the night for 8–12 hours using a pump, or the whole 24 hours using an elastomeric pump infuser, has been tested in 11 thalassemia patients (seven males, four females) over a period of 9–28 months. The patients had variable serum ferritin levels (0.54–4.6 mg/L) and cardiac iron load ranging from normal to severe siderosis levels (MRI T2*: 4.7–45 ms). There was a substantial overall reduction in serum ferritin levels (0.17–2.16 mg/L) and normalization of cardiac iron (MRI T2* >20 ms) in all patients. In two patients with severe and moderate cardiac iron load range levels, cardiac iron normalization was achieved within 9–10 months. Two patients on L1 monotherapy (80–120 mg/kg/day) maintained normal range MRI T2* cardiac iron levels over the same period. The ICOC combination therapy protocol appears to be the most effective and least cumbersome form of chelation treatment for the rapid clearance of excess iron from the heart.

Keywords:

• International Committee on Oral Chelators (ICOC) protocol
• Chelation therapy
• Deferiprone (L1)
• Deferoxamine (DFO)
• Combination therapy
• Thalassemia
• Iron overload

Notes

24. Grady RW. An update on development of new iron-chelating drugs. Abstract Book. Proceedings of the 15th ICOC April 22–26, 2005, Taichung, Taiwan. 2005; 66